Phase I-II study of intratumor immunotherapy with BCG cell wall skeleton plus P<inf>3</inf>

S. P. Richman, J. U. Gutterman, Evan M Hersh, E. E. Ribi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A vaccine composed of BCG cell wall skeleton (CWS) and a trehalose dimycolate called P<inf>3</inf>, attached to microdroplets of mineral oil, was evaluated for activity and toxicity when injected into tumor nodules. A total of 99 nodules in 23 patients with metastatic melanoma and carcinoma of the breast were treated overa dose range of 150 μg, 300 μg, and 600 μg cell wall skeleton plus P<inf>3</inf> per cm of nodule diameter. At least one injected nodule resolved in 11 of the 23 patients (48%), and 34% of all injected nodules resolved. Response correlated with nodule size of 1 cm or less, cutaneous location, and immunocompetence measured by PPD and recall skin testing. Toxicity became manifest in ulceration (61% of patients), fever (52%), and pain (26%).

Original languageEnglish (US)
Pages (from-to)41-44
Number of pages4
JournalCancer Immunology, Immunotherapy
Volume5
Issue number1
DOIs
StatePublished - 1978
Externally publishedYes

Fingerprint

Cell Wall Skeleton
Mycobacterium bovis
Immunotherapy
Cord Factors
BCG Vaccine
Immunocompetence
Mineral Oil
Skin
Tuberculin
Melanoma
Fever
Breast Neoplasms
Pain
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Phase I-II study of intratumor immunotherapy with BCG cell wall skeleton plus P<inf>3</inf> / Richman, S. P.; Gutterman, J. U.; Hersh, Evan M; Ribi, E. E.

In: Cancer Immunology, Immunotherapy, Vol. 5, No. 1, 1978, p. 41-44.

Research output: Contribution to journalArticle

@article{73e700d704a9471a9927df0db8d85d79,
title = "Phase I-II study of intratumor immunotherapy with BCG cell wall skeleton plus P3",
abstract = "A vaccine composed of BCG cell wall skeleton (CWS) and a trehalose dimycolate called P3, attached to microdroplets of mineral oil, was evaluated for activity and toxicity when injected into tumor nodules. A total of 99 nodules in 23 patients with metastatic melanoma and carcinoma of the breast were treated overa dose range of 150 μg, 300 μg, and 600 μg cell wall skeleton plus P3 per cm of nodule diameter. At least one injected nodule resolved in 11 of the 23 patients (48{\%}), and 34{\%} of all injected nodules resolved. Response correlated with nodule size of 1 cm or less, cutaneous location, and immunocompetence measured by PPD and recall skin testing. Toxicity became manifest in ulceration (61{\%} of patients), fever (52{\%}), and pain (26{\%}).",
author = "Richman, {S. P.} and Gutterman, {J. U.} and Hersh, {Evan M} and Ribi, {E. E.}",
year = "1978",
doi = "10.1007/BF00199206",
language = "English (US)",
volume = "5",
pages = "41--44",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Phase I-II study of intratumor immunotherapy with BCG cell wall skeleton plus P3

AU - Richman, S. P.

AU - Gutterman, J. U.

AU - Hersh, Evan M

AU - Ribi, E. E.

PY - 1978

Y1 - 1978

N2 - A vaccine composed of BCG cell wall skeleton (CWS) and a trehalose dimycolate called P3, attached to microdroplets of mineral oil, was evaluated for activity and toxicity when injected into tumor nodules. A total of 99 nodules in 23 patients with metastatic melanoma and carcinoma of the breast were treated overa dose range of 150 μg, 300 μg, and 600 μg cell wall skeleton plus P3 per cm of nodule diameter. At least one injected nodule resolved in 11 of the 23 patients (48%), and 34% of all injected nodules resolved. Response correlated with nodule size of 1 cm or less, cutaneous location, and immunocompetence measured by PPD and recall skin testing. Toxicity became manifest in ulceration (61% of patients), fever (52%), and pain (26%).

AB - A vaccine composed of BCG cell wall skeleton (CWS) and a trehalose dimycolate called P3, attached to microdroplets of mineral oil, was evaluated for activity and toxicity when injected into tumor nodules. A total of 99 nodules in 23 patients with metastatic melanoma and carcinoma of the breast were treated overa dose range of 150 μg, 300 μg, and 600 μg cell wall skeleton plus P3 per cm of nodule diameter. At least one injected nodule resolved in 11 of the 23 patients (48%), and 34% of all injected nodules resolved. Response correlated with nodule size of 1 cm or less, cutaneous location, and immunocompetence measured by PPD and recall skin testing. Toxicity became manifest in ulceration (61% of patients), fever (52%), and pain (26%).

UR - http://www.scopus.com/inward/record.url?scp=0018063854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018063854&partnerID=8YFLogxK

U2 - 10.1007/BF00199206

DO - 10.1007/BF00199206

M3 - Article

AN - SCOPUS:0018063854

VL - 5

SP - 41

EP - 44

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -